REHOVOT, Israel, Sept. 6,
2022 /PRNewswire/ -- CollPlant
Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic
medicine company developing innovative human collagen-based
technologies and products for tissue regeneration and organ
manufacturing, today announced that Deputy CEO and CFO Eran Rotem will participate in investor
conferences later this month.
- HC Wainwright 24th Annual Global Investment
Conference: Participate in investor meetings on Monday and
Tuesday, September 12-13.
- Alliance Global Partners MedTech Conference: Virtual
investor meetings on Wednesday, September
21.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. The Company's products are based on its rhCollagen
(recombinant human collagen) produced with CollPlant's proprietary
plant based genetic engineering technology. These products address
indications for the diverse fields of tissue repair, aesthetics,
and organ manufacturing, and are ushering in a new era in
regenerative and aesthetic medicine.
At the beginning of 2021, CollPlant entered into a development
and global commercialization agreement for dermal and soft tissue
fillers with Allergan, an AbbVie company, the global leader in the
dermal filler market. Later in 2021, CollPlant entered a strategic
co-development agreement with 3D Systems for a 3D bioprinted
regenerative soft tissue matrix for use in breast reconstruction
procedures in combination with an implant.
For more information about CollPlant, visit
http://www.collplant.com/
Photo -
https://mma.prnewswire.com/media/1772558/CollPlant.jpg
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
View original
content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-to-participate-in-september-investor-conferences-301618106.html
SOURCE CollPlant